4basebio (LON:4BB) Shares Up 3.5% – Here’s What Happened

Shares of 4basebio PLC (LON:4BBGet Free Report) rose 3.5% during trading on Friday . The stock traded as high as GBX 496.80 and last traded at GBX 496.80. Approximately 38 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 1,267 shares. The stock had previously closed at GBX 480.

Analysts Set New Price Targets

Separately, Royal Bank Of Canada lowered their price objective on shares of 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating on the stock in a research report on Monday, June 15th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of GBX 1,400.

Read Our Latest Report on 4basebio

4basebio Trading Up 3.5%

The company has a 50 day simple moving average of GBX 510.10 and a 200 day simple moving average of GBX 510.47. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47. The stock has a market capitalization of £76.93 million, a PE ratio of -4.56 and a beta of 1.09.

About 4basebio

(Get Free Report)

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.

Further Reading

Receive News & Ratings for 4basebio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4basebio and related companies with MarketBeat.com's FREE daily email newsletter.